RecruitingPhase 4NCT07696793

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy

Efficacy and Tolerability of a Simethicone-containing Evacuating Solution for Colorectal Cancer Screening Colonoscopy: a Randomized Parallel Comparative Trial CLEAN+

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Enrollment

818 participants

Start Date

May 18, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal Cancer Early Detection

Summary

Study to evaluate the efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy.

Eligibility

Min Age: 50 YearsMax Age: 69 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Citrafleet® and a drug called Clensia® for people with colorectal cancer early detection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years to 69 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClensia®

Participants will take the treatment in two doses, 4 sachets dissolved in 200cc of water 9-12 hours before the examination and 4 sachets dissolved in 200cc of water 4 hours before the examination.

DRUGCitrafleet®

Participants will take the treatment in two doses, 1 sachet dissolved in 200cc of water 9-12 hours before the examination and 1 sachet dissolved in 200cc of water 4 hours before the examination.

Locations(1)

Hospital Clínic de Barcelona

Barcelona, Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07696793